Brain sonography features in X-linked dystonia-parkinsonism

A. Rocco^{1,2}, U. Walter¹, C. Klein³, R. Rosales⁴, C. Go^{4,5}, D. Dressler⁶, L.V.Lee⁴

¹ Neurology Section, Department of System Medicine, University of Rome "Tor Vergata", Italy

² Department of Neurology, University of Rostock, Germany

³ Institute of Neurogenetics, University of Lübeck, Lübeck, Germany

⁴ XDP Study Group, Philippine Children's Medical Center, Quezon City, Philippines;

⁵ Faculty of Neurology and Psychiatry, University of Santo Tomas, Manila, Philippines

⁶ Movement Disorders Section, Department of Neurology, Hannover Medical School, Hannover, Germany



Tor Vergata

Introduction Patients X-linked recessive dystonia-parkinsonism (XDP, Lubag, DYT3) is Altogether, 89 participants (36 female; mean age 45.1 ± 12.9 years) were enrolled. Participants were classified with a rare movement disorder that is highly prevalent in the Philippines. XDP has been associated with different genetic respect to family history, mutational status, and clinical mutations on the X chromosome not yet unequivocally determined symptoms of XDP. 40 participants were clinically affected XDP patients with and with morphological and functional evidence of an positive genetic status, 20 were clinically unaffected relatives involvement of the dopaminergic nigrostriatal pathway (1, 2). of XDP patients (7 with positive genetic status, 7 with Here, we evaluated the correlation between transcranial brain


sonography (TCS) findings and the genetic and clinical state in XDP patients, relatives and controls.

negative genetic status, 6 with unknown genetic status), and 29 served as healthy controls.

Methods

Sonography.

Ultrasound system: Esaote MyLab 25 Gold; 2.5-MHz phased-array transducer. Investigation: Transtemporally in three axial scans (Fig.). SN size measurements were performed on axial midbrain scan automatically after manually encircling SN's outer circumference. SN sizes < 0.20 cm² were classified as normal, sizes ≥ 0.25 cm² as markedly hyperechogenic, and sizes in between as moderately hyperechogenic. Echogenicity of the lenticular nuclei (LN) was classified as hyperechogenic when it was more intense than the surrounding white matter (3). SN and LN echogenicity was quantified post-hoc on digitized analysis of anonymized images using Math-Lab based software. **Statistics**. Descriptive statistics; chi-square test, Fisher exact test.



Cella-media axial scan: Width of the lateral ventricle (cella media) is measured contralaterally.

Diencephalic axial scan: Investigation of the contralateral thalamus, lenticular and caudate nuclei, widths of the third ventricle and the contralateral frontal horn of the lateral ventricle.


Mesencephalic axial scan: Measurement of ipsilateral SN echogenic area, evaluation of nucleus ruber and midbrain raphe.


TCS of brain parenchyma: Transtemporal investigation on three axial scans

Results

Relationship between TCS findings and clinical status

27 (79%) of 34 assessable, clinically affected XDP patients exhibited SN+ but only 9 (53%) of 17 relatives of XDP patients and 9 (38%) of 24 healthy control subjects (p = 0.005).





30 (81%) of 37 assessable, clinically affected XDP patients exhibited 7 (28%) of LN+ but only 4 (25%) of 16 relatives of XDP patients and 25 healthy control subjects (p < 0.001).

Relationship between TCS findings and mutational status

31 (78%) of 40 assessable patients with XDP mutation exhibited SN+ but only 10 (34%) of 29 subjects without mutation (p < 0.001).

Considering only the unaffected relatives of XDP patients, 4 (67%) of 6 assessable subjects with XDP mutation exhibited SN+ but only 1 (20%) of 5 subjects without mutation (p < 0.001). By contrast, only 2 (40%) of 5 assessable subjects with XDP mutation exhibited LN+ and 1 (20%) of 5 subjects without mutation (p = 0.50).

Conclusions

- **SN and LN alteration are frequent sonographic features in XDP.**
- SN alteration may be a diagnostic marker already in presymptomatic disease stages. \bullet
- LN is affected predominantly in the symptomatic stages.

References:

(1) Domingo A et al. *Eur J Hum Genet* 2015 Jan 21. doi: 10.1038/ejhg.2014.292. (2) Tackenberg B et al. *Mov Disord* 2007;22(6):900-902.





XLVI CONGRESSO NAZIONALE

10-13 OTTOBRE 2015 – GENOVA

